Dotinurad - Fuji Yakuhin/Mochida Pharmaceutical
Alternative Names: FYU-981; Urece; YurisuLatest Information Update: 20 Jul 2024
At a glance
- Originator Fuji Yakuhin
- Developer Eisai Co Ltd; Fortress Biotech; Fuji Yakuhin; Mochida Pharmaceutical; Urica Therapeutics
- Class Antigouts; Benzothiazoles; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gout; Hyperuricaemia
Most Recent Events
- 12 Jun 2024 Efficacy and adverse events data from a phase III trial in Gout presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 10 Nov 2023 Updated pharmacokinetics data from a phase I trial presented at the ACR Convergence 2023 (ACR 2023)
- 01 Oct 2023 Urica Therapeutics initiates a phase I/II trial for Gout and Hyperuricemia in USA (NCT06056570)